April 23, 2018 Licensing, IP, and Legal Product Launch

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis

Basel, 23 April 2018 New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis Four years of continuous treatment with OCREVUS showed a sustained reduction in underlying disease activity in relapsing MS (RMS) in analysis from the open-label extension period Additional analyses show OCREVUS delayed cognitive... Read more

April 23, 2018 Licensing, IP, and Legal Product Launch

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis

Basel, 23 April 2018 New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis Four years of continuous treatment with OCREVUS showed a sustained reduction in underlying disease activity in relapsing MS (RMS) in analysis from the open-label extension period Additional analyses show OCREVUS delayed cognitive... Read more

April 16, 2018 Atomic Spectroscopy Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline

Basel, 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s... Read more

April 16, 2018 Atomic Spectroscopy Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline

Basel, 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s... Read more

April 13, 2018 Lab Top-10 Licensing, IP, and Legal Life Science Tools

Illumina Investigation Initiated by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. – ILMN

NEW ORLEANS, April 13, 2018 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Illumina, Inc. (Nasdaq: ILMN). During the first two quarters of 2016, the Company, which provides genetic sequencing products to customers in the... Read more

April 3, 2018 Lab Top-10 Licensing, IP, and Legal Liq. Handling & Robotics

Rapid Mycoplasma Testing Method Now Accepted by Regulators for QA/QC and Lot Release

Rapid Mycoplasma Testing Method Now Accepted by Regulators for QA/QC and Lot Release MycoSEQ Mycoplasma Detection Method can accelerate production timelines for manufacturers of cell and gene therapies, biotherapeutics, vaccines and other cell-culture-based modalities BEDFORD, Mass., April 3, 2018 /PRNewswire/ — Manufacturers of cell-culture-based therapeutics can now rely on a faster method for detecting mycoplasma contamination.... Read more